Remes-Troche JM, Rodríguez-González B, Valdovinos-Díaz MA

Language: Spanish
References: 55
Page: 151-159
PDF size: 92.24 Kb.

ABSTRACT

Introduction/aim: Gastroesophageal reflux disease (GERD) is one of the most common gastrointestinal disorders. Up to 40% of the adult population has heartburn at least once per month, 20% once per week and 7% daily. Because most of the GERD patients take medications that inhibit the acid secretion, the economic impact of this disorder is high. In addition, GERD symptoms impact negatively the quality of life. Although GERD is a world-wide problem, information about this disease is scarce in Mexico. The aim of this study was to undertake a systematic review of all the relevant original literature available about GERD in our country. Methods: All studies which originated in Mexico and were published in the Spanish and/or English languages were identified by an electronic search of Imbiomed and Medline from 1996 to 2000. A search for the medical subject headings, gastro esophageal reflux disease, erosive esophagitis, non-erosive reflux disease, hiatus hernia and Barrett esophagus; limited by the term, Mexico, was done. We included original and review studies in both adult and pediatric population. Data were organized in items of interest: epidemiology, physiopathology, clinical manifestations, diagnosis, treatment, and prognosis. For each item, an introduction of known data was used as the framework for the description of the Mexican data. A qualitative analysis of the available literature was performed according to 3 levels of evidence: type I (excellent), type II (good) and type III (poor). Results: A total of 48 publications were identified, the majority Publisher between 1995 and 2005. Eighty-five percent of the publications were performed in adult population, 13% in pediatric population ad 2% were experimental models. There were 10 original articles (21%) about physiopathology, eight (17%) about clinical manifestations, 11 (22%) about diagnostic procedures, nine (19%) about treatment, and 10 (21%) regarding complications. There were not studies about epidemiology or prognosis. Of the 48 studies, only one (2%) was evidence type I, 14 (29%) evidence type II, and 33 (69%) evidence type III. Conclusions: Most of the studies about GERD in our population lack of a good level of evidence (type III). However, we can conclude that clinical presentation (typical or atypical) of GERD in our population is similar to others populations. Available diagnostic procedures are useful to confirm GERD diagnosis in our population. Medical treatment, epidemiology, prognosis and GERD related complications studies are scarce. Further investigations in these issues are required in our country.

REFERENCES

1. Locke GR III, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmstead County, Minnesota. Gastroenterology 1997; 112: 1448-56.

2. A Gallup Organization National Survey. Heartburn Across America. Princeton, NJ: Gallup; 1988.

3. Nebel OT, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: incidence and precipitating factors. Am J Dig Dis 1976; 21: 953-6.

4. Graham DY, Smith JL, Patterson DJ. Why do apparently healthy people use antiacids tablets? Am J Gastroenterol 1983; 78: 257-60.

5. Harris RP, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force: A review of the process. Am J Prev Med 2001; 20(Suppl. 3): 21-35.

6. Gomez EO, Herrera HMF, Valdovinos DMA. Obesity and gastroesophageal reflux disease Rev Invest Clin 2002; 54(4): 320-7.

7. Carmona-Sanchez R, Navarro-Cano G. Prevalence of Helicobacter pylori infection in patients with reflux esophagitis. A case-control study. Rev Gastroenterol Mex 2003; 68(1): 23-8.

8. Nogueira-de Rojas JR, Jimenez-Gonzalez A, Cervantes-Solis C. Helicobacter pylori gastric infection is a protection factor for gastroesophageal reflux disease. Rev Gastroenterol Mex 2002; 67(1): 22-7.

9. Icaza ME, Soto JC, Pedroza J, Valdovinos MA. Ineffective motility in lower third of esophagus. Length of involved esophagus and severity of gastroesophageal reflux disease. Rev Gastroenterol Mex 2003; 68(1): 34-40.

10. Valdovinos DMA, Flores C, Facha MT, Koller LJ. Esophageal manometry in gastroesophageal reflux disease. Lower esophageal sphincter incompetence or esophageal dismotility? Rev Gastroenterol Mex 1999; 64(1):16-8.

11. Alvarez CR, Martín MA, Chávez GM, Pérez VE, Ortiz SA, Trinidad HS, López GJ. Correlación clínica, morfológica y funcional en pacientes con reflujo gastroesofágico. Rev Hosp Jua Mex 2003; 70(1): 7-13.

12. Remes-Troche JM, Gomez-Escudero O, Ruiz JC, Schmulson MJ, Valdovinos Diaz MA. Perception of symptoms with minimal reductions of esophageal pH in patients with erosive and non-erosive GERD. Rev Gastroenterol Mex 2004; 69(1): 30-6.

13. Niva VCO, Quiroga VH, Arenas OJ. Enfermedad por reflujo duodenogastroesofágico y esofagitis. Cir Ciruj 2003; 71(4): 286-95.

14. Acevedo-Nuno E, González-Ojeda A, Vázquez-Camacho G, et al. Human papillomavirus DNA and protein in tissue simples of oesophageal cancer, Barrett’s oesophagus and oesophagitis. Anticancer Res 2004; 24(2C): 1319-23.

15. Ortega SJA, Villegas AF, de la Garza RAS. ¿Son los modelos animales adecuados para indagar la causa de la enfermedad por reflujo gastroesofágico? Acta Pediatr Mex 2004; 25(1): 4-8

16. Soto PJC, Icaza ME, Vargas F, Valdovinos DMA. Non-erosive gastroesophageal reflux disease. Incidence of clinical forms, characteristics of esophageal exposure to acid and symptomatic correlations. Rev Gastroenterol Mex 2003; 68(2): 113-9.

17. Carmona-Sánchez R, Solana-Sentíes S, Esmer-Sánchez D, Tostado-Fernández JFA. La prevalencia de los diferentes grupos que integran la enfermedad por reflujo con endoscopia negativa. Rev Gastroenterol Mex 2005; 70(1): 6-13.

18. Iniestra FF, Gomez VJ, Orea SM, Flores SG, Cruz PMdel C. Gastroesophageal reflux disease in pediatric patients with asthma. Rev Alerg Mex 2002; 49(5): 152-6.

19. Carmona-Sanchez R, Valdovinos-Diaz MA, Facha MT, Aguilar L, Cachafeiro M, Solana S, Carrillo G, Chapela R, Mejia M, Perez-Chavira R, Salas J. Hiatal hernia in asthmatic patients: prevalence and its association with gastroesophageal reflux. Rev Invest Clin 1999; 51(4): 215-20.

20. Carmona-Sanchez R, Valdovinos-Díaz MA, Facha MT y cols. Gastroesophageal reflux in asthmatic patients: an incident study and clinical correlation. Gac Med Mex 1999; 135(5): 471-5.

21. Mogica MMD, Paredes CE, Tenorio PMA, Rodríguez CJ, Molina OC, del Rosario CRM, Lopez DJL, Becerril AM. Prevalence of hiatal hernia and chronic esophagitis in adult asthmatic patients. Rev Alerg Mex 2001; 48(5): 145-50.

22. Suazo J, Facha MT, Valdovinos MA. Case and control study of atypical manifestations in gastroesophageal reflux disease. Rev Gastroenterol Mex 1998; 317-22.

23. Aguilar-Paiz LA, Valdovinos-Díaz MA, Flores-Soto C, Carmona-Sánchez R, Vargas-Vorackova F, Herrera MF, de la Garza-Villaseñor L. Rev Invest Clin 1999; 51(6): 345-50.

24. Valdovinos DMA, Gomez EO. New diagnostic procedures in gastroesophageal reflux disease: from Bernstein test to impedance. Rev Gastroenterol Mex 2003; 68(Suppl. 3): 4-11.

25. Ramírez MJA, de la Torre ML, Azuara FH, et al. Consenso médico quirúrgico para el manejo de niños con reflujo gastroesofágico –Acapulco, México, 2002–. Rev Gastroenterol Mex 2003; 68(3): 223-34.

26. Uscanga L, Nogueira-de-Rojas R, Gallardo E, Bernal-Reyes R, González M, Ballesteros-Amozurrutia A y el Grupo Mexicano para el Estudio de la Enfermedad por Reflujo Gastroesofágico. Rev Gastroenterol Mex 2002; 67(3): 216-23.

27. Gomez-Escudero O, Remes-Troche JM, Ruiz JC, Pelaez-Luna M, Schmulson MJ, Valdovinos DMA. Diagnostic usefulness of the Carlsson-Dent questionnaire in gastroesophageal reflux disease (GERD). Rev Gastroenterol Mex 2004; 69(1): 16-23.

28. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, et al. Omeprazole as a diagnostic tool in gastroesophageal reflux disease. Am J Gastroenterol 1997; 92: 1997-2000.

29. Fass R, Ofman JJ, Gralnek IM, et al. Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease. Arch Intern Med 1999; 159: 2161-8.

30. Numans ME, Lau J, de Wit NJ. Bonis PA. Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease. Ann Intern Med 2004; 140: 518-27.

31. Remes-Troche JM, Carmona-Sánchez R, Soto PJ, González M, Icaza ME, Valdovinos-Díaz MA. Diagnóstico de las diferentes variedades de la enfermedad por reflujo no erosiva (ERNE) mediante pHmetría y prueba de rabeprazol. Estudio Multicéntrico Nacional. Rev Gastroenterol Mex 2005 (en prensa).

32. Carmona-Sánchez R, Facha GMT, Valdovinos-Díaz MA. ¿Por qué se solicita la pHmetría esofágica? Comparación con las recomendaciones de la Asociación Americana de Gastroenterología para su uso correcto. Rev Gastroenterol Mex 1998; 63(2): 93-6.

33. Teramoto MO. Utilización de un sistema inalámbrico para medición del pH esofágico, ¿es realmente necesario? Rev Mex Cir Endoscop 2004; 5(3): 127-30.

34. Carmona-Sanchez R, Solana-Senties S. Efficacy, diagnostic utility and tolerance of intraesophageal pH ambulatory determination with wireless pH-testing monitoring system. Rev Gastroenterol Mex 2004; 69(2): 69-75.

35. Valdovinos DMA, Remes TJM, Ruiz AJC, Schmulson MJ, Valdovinos-Andraca F. Successful esophageal pH monitoring with Bravo capsule in patients with gastroesophageal reflux disease. Rev Gastroenterol Mex 2004; 69(2): 62.

36. Remes-Troche JM, Ibarra-Palomino J, Carmona-Sánchez RI, Valdovinos-Díaz MA. Performance, tolerability and symptoms related to prolonged pH monitoring using the Bravo system in Mexico. Am J Gastroenterol 2005 (In press).

37. Soria GJE, Gomes VJ, Cruz PMC, Flores SG, Orea SM. Asma y reflujo gastroesofágico. Correlación entre gammagrafía y endoscopia digestiva. Rev Alerg Mex 2001; 48(2): 48-55.

38. Córdoba-Villalobos JA, Ramírez-Barba E, Ramírez-Covarrubias JC. Esofagitis por reflujo: Estudio comparativo entre lansoprazol y omeprazol como terapia a corto plazo, informe preliminar. Rev Gastroenterol Mex 1996; 61(4): 306-9.

39. Gallo S, Dibildox M, Moguer A, Di Silvio M, Rodríguez F, Almaguer I, García C y el grupo Mexicano de Estudio del Pantoprazol. Superioridad clínica del pantoprazol sobre la ranitidina en la curación de la esofagitis por reflujo grado II y III. Estudio prospectivo, doble ciego, doble placebo. Experiencia mexicana. Rev Gastroenterol Mex 1998; 63(1): 11-16.

40. Ramírez Mayans JA, Galis Vietez P, Piña Romero N. Acta Pediatr Mex 2000; 21(5): 155-9.

41. González AMA, Díaz de León FCF, Moreno GJS. Rev Fac Med UNAM 2001; 44(2): 55-7.

42. Ortiz de la Pena RJ, Orozco OP, de la Fuente LM, Goldberg DJ. Tratamiento quirúrgico de la enfermedad por reflujo gastroesofágico. An Med Asoc Med Hosp ABC 2001; 46(4): 180-2.

43. Bernal-Gomez R, Olivares-Ontiveros O, Garcia-Vazquez A y cols. Laparoscopic management of gastroesophageal reflux disease. Experience with 100 cases. Rev Gastroenterol Mex 2001; 66(2): 80-5.

44. Chousleb KA, Shuchleib ChS, Heredia CNM y cols. Reflujo gastroesofágico. Tratamiento quirúrgico con técnicas de invasión mínima. Rev Mex Cir Endoscop 2001; 2(2): 47-51.

45. Gómez CX, Flores AJH, Di Martino AE y cols. Resultados a largo plazo de dos técnicas laparoscópicas antirreflujo. Rev Mex Cir Endoscop 2004; 5(3): 121-6.

46. Soto CJC, García SMAX, Contreras RO y cols. Prevalencia del esófago de Barrett y asociación con adenocarcinoma de esófago: Experiencia de 25 años. Rev Fac Med UNAM 2000; 43(2): 52-4.

47. Peña ANG, Manrique MA, Chávez-García MA, Pérez VE, Ladrón de Guevara L, López GJ. Prevalencia de esófago de Barrett en pacientes no seleccionados sometidos a esofagogastroduodenoscopia y factores de riesgo asociados. Rev Gastroenterol Mex 2005; 70: 20-4.

48. Trujillo-Benavides O, Baltasar MP, Ángeles-Garay U y cols. Asociación entre reflujo gastroesofágico sintomático y esófago de Barrett. Rev Gastroenterol Mex 2005; 70: 14-19.

49. López AME, Rodríguez VG, Farca BA, De la Mora LG, Presenda MF, Gónzalez AR. Diagnóstico, seguimiento y tratamiento endoscópico del esófago de Barrett. Rev Mex Cir Endoscop 2001; 2(2): 52-62.

50. Remes-Troche JM, Ramírez-Arias JF, Gómez-Escudero O, Valdovinos-Andraca F, Vargas-Vorackova F. ¿La vigilancia endoscópica recomendada en pacientes con esófago de Barrett es una estrategia costo-efectiva? Rev Gastroenterol Mex 2005 (en prensa).

51. Tehozol ME, Manrique MA, Chávez GM y cols. Evaluación prospectiva de la cromoendoscopia con aplicación de azul de metileno para identificar esófago de Barrett de segmento corto. Rev Hosp Jua Mex 2003; 70(3): 99-103.

52. Skromne KG, Hidalgo RR. Azul de metileno radiactivo para el diagnóstico de esófago de Barrett. Rev Hosp Jua Mex 2004; 71(4): 156-7.

53. Mendoza-Ramón H, Goldberg J, Slomianski A, Leal G, Ortiz-Hidalgo C. Presencia de páncreas acinar en reflujo y esófago de Barrett. Rev Gastroenterol Mex 1998; 63(3): 143-7.

54. Sandoval AI, Alfaro FLG, Bermúdez RH y cols. Prevalencia de esófago de Barrett en pacientes con carcinoma colorrectal. Rev Gastroenterol Mex 2001; 66: 126-30.

55. Beltrán BF, Catalán LJ, Nobigrot KD, Bierzwinski KA, Himmelman GM, Nobigrot M. Reflujo gastroesofágico. Presentación de casos clínicos con complicaciones. Acta Pediatr Mex 1996; 17(1): 13-16.